[Possibility of using 131I-meta-iodobenzylguanidine in the diagnosis of neuroendocrine tumors differing from pheochromocytomas].
The results obtained using 131I-MIBG to diagnose different neuroendocrine tumors in 17 patients are discussed. In 8 of the neuroblastomas studied the examination gave a wide spectrum of scintigraphic results according to the various stages of evolution of the tumors, thus supplying additional useful information for metabolic treatment. Contradictory data were obtained in 5 cases of medullary cancer of the thyroid. The overall results were unexpectedly negative for 2 carcinoid tumors and, as expected, negative for 2 ganglioneuromas. These data confirm that 131I-MIBG is a non invasive, reliable and easy-to-perform technique which is no longer limited to the diagnosis of pheochromocytomas, but can also be used for the diagnosis of other tumors derived from neural crest cells.
D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging*; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000000981:diagnostic imaging*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007462:Iodobenzenes; D008297:Male; D008875:Middle Aged; D009447:Neuroblastoma / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*
D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine
Possibilità di impiego della 131I-MIBG nella diagnostica di tumori neuroendocrini diversi dai feocromocitomi.